Osteopore Ltd. · ASX:OSX
Osteopore — Investor Presentation (October 2019)
30 slides from Osteopore's investor presentation, Oct 22, 2019
Slide 1: Investor Presentation - October 2019
For personal use only Breakthrough 3D printed bioresorbable implants to assist with the natural stages of bone healing. Osteopore Limited (ASX: OSX) Investor Presentation - October 2019
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Osteopore Limited and its related entities (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not tr
Slide 3: Company Overview
Osteopore Limited (ASX: OSX) – Company Overview For personal use only Osteopore Limited (ASX: OSX) is an Australian / Singapore-based medical technology company that specialises in the production of 3D printed bioresorbable implants to assist with the natural stages of bone healing. Osteopore’s prod
Slide 4: Corporate and Capital Structure
Osteopore Limited (ASX: OSX) For personal use only Corporate and Shares on Issue 101.2m Capital Structure Capital Structure Total Options on Issue 9.7m o No debt Market Cap @ $0.815c* $82.5m o 51.4m shares under escrow for 12-24 EV @ $0.815c* $77.3m months o Options could provide an Current Cash Bal
Slide 5: Investment Highlights
Osteopore Limited (ASX: OSX) For personal use only 5 Investment Highlights Revenue Generating Proprietary Technology Scalable Business Model Approximately AUD$990,000 in revenues Osteopore has licensed a range of patented High margin products with low capital for the twelve month period to 31 Decemb
Slide 6: Management and Board of Directors
Osteopore Limited (ASX: OSX) Partner of Ventnor Capital Brett Sandercock and Non-Executive Founder, Management Chairman and Director of For personal use only Non-Exec Chairman various ASX listed entities and Board of Directors Current CFO of Resmed (ASX:RMD / NYSE: RMD) and Senior executive at Stuar
Slide 7: Tissue engineering, 3D printed microarchitecture and regenerative medicine
For personal use only Tissue engineering, 3D printed microarchitecture and regenerative medicine concepts are at the heart of the Osteopore technology. Osteopore Limited (ASX: OSX) Regenerative medicine treats injuries and diseases by Regenerative Medicine harnessing the body’s own regenerative capa
Slide 8: Customisable 3D printed bioresorbable implants
For personal use only Customisable 3D printed bioresorbable implants to enable the natural stages of bone healing across multiple applications. Highly customisable Naturally dissolves Leaves only healthy Reduces post surgery Unlikely inflammation to biomimic different over time bone tissue complicat
Slide 9: Proprietary Bioresorbable Scaffold Technology
Osteopore Solution Proprietary Bioresorbable For personal use only Scaffold Technology Osteopore’s proprietary 3D printed polymer scaffold is Osteopore Scaffold made up of biomimetic microstructures that facilitate natural tissue regeneration after insertion into the human body. Angiogenesis – Early
Slide 10: Current Approaches to Bone Regeneration
Osteopore Solution For personal use only Current Approaches to Bone Regeneration Currently, there are three main treatment Bone Grafit Permanent Implants Bio-Materials strategies to augment the bone-regeneration process, including the 'gold standard' bone A surgical procedure where bone Permanent ma
Slide 11: Products & Applications
Osteopore Solution 11 Products & Applications For personal use only Bioresorbable implant that is Bioresorbable implant that is used in Provides a durable, biodegradable Patient Specific Implants (PSI) based on used for covering Burr Holes craniofacial surgery to repair various method of filling the
Slide 12: Proven to Facilitate Bone Healing – Burr Hole Example
1 Month Post-Operation CT Imagery Patients needing surgical repair for skull fractures For personal use only usually receive a “burr hole” during surgery, which is drilled into the skull to relieve pressure from haemorrhage. To repair the burr hole, common methods include harvesting bone from anothe
Slide 13: Clinical Success For Patient Specific Implants
Osteopore Solution For personal use only Clinical Success For Patient Specific Implants Bone Defect Early Mineralisation Walking Bone Remodeling 150mm bone loss due to Initial osseous ingrowth with Able to walk without Complete bone bridging tumor resection 20kg partial weight-bearing assistance fro
Slide 14: Osteopore Offers Unique Therapeutic Value Proposition
Osteopore Solution 14 Osteopore Offers Unique Therapeutic Value Proposition For personal use only There are no other FDA or CE Mark cleared products that offer Microporous Osteopore’s key technology characteristics – bio-resorption and (Biomimetic Structure) biomimetic structure - which offer improv
Slide 15: Market Opportunities & Growth Strategy
For personal use only Market Opp rtunities & Growth Strategy
Slide 16: Business and Revenue Model
Market Opportunity & Growth Strategy For personal use only Business and Revenue Model Distribution Networks Given the high wholesale margins and low capital intensity of the 3-D printing-based manufacturing process, Osteopore is focused on building distribution networks for its products while retain
Slide 17: Opportunities in Multi-Billion Dollar Global Markets
Market Opportunity & Growth Strategy Opportunities in Multi-Billion For personal use only Dollar Global Markets Current Sales Current market opportunities Current sales of Osteopore products are pre- (Bone Graft substitutes, US$3.9bn by 2025) dominantly in Cranial / Maxillofacial (CMF) area, Permane
Slide 18: Revenue Growth Strategy
Market Opportunity & Growth Strategy 18 Revenue Growth Strategy For personal use only Osteopore is now looking to build value through short, medium and long term strategic goals. Revenue Expansion o Growth in revenue from existing Asian markets Phase One Increase underlaying revenue from its o Estab
Slide 19: Phase One: Revenue Expansion
19 Revenue Growth Strategy For personal use only Phase ne Revenue Expansion The Company aims enhance market penetration of the Phase Two commercially ready Osteoplug, Osteomesh and Osteostrip products Phase Three Building underlying revenue base organically from Asian markets and building distributi
Slide 20: Phase Two: New Therapeutic Segments
20 Phase Two Revenue Growth strategy For personal use only Phase Tw New Therapeutic Segments Expand Osteopore’s product offering with new applications that are complementary to Phase Three the Osteomesh, Osteoplug and Osteostrip products – dental and spinal/orthopaedic market segments. Dental Longbo
Slide 21: Phase Three: Future Horizons
21 Phase One Phase Two Revenue Growth strategy For personal use only Phase Three Future Horizons Accelerating Bone Regeneration Osteopore is investigating the viability of incorporating additional materials into new polycaprolactone polymer material which could be used to improve patient outcomes. T
Slide 22: Building blocks in place for executing growth strategy
For personal use only Building bl cks in place for executing growth strategy
Slide 23: Scalable & Customisable Manufacturing
Building blocks for execution Integration of Medical Imaging, Computational For personal use only Mechanics & Biomaterials Technology Scalable & Customisable Step One Manufacturing The hospital undertakes a CT scan. Step Two Osteopore uses third party software to digitise the 3D printing process to
Slide 24: Global Regulatory Approval
For personal use only Building blocks for execution Global Regulatory Approval Current regulatory clearances Potential Future clearances 24
Slide 25: Intellectual Property
Building blocks for execution Intellectual Property For personal use only Osteopore technology is supported by granted patents from leading Singaporean research institutions. Method for Bioresorbable 3-D Bioresorbable Resorbable Bioresorbable- Fabricating a Plug Implants Scaffolds for Tissue Scaffol
Slide 26: Research & Development Partners
For personal use only Building blocks for execution Research & Development Partners Osteopore has exclusive license arrangements with Nanyang Technological University (NTU), National University of Singapore (NUS) and Temasek Polytechnic. And a number of key research and development relationships wit
Slide 27: Media & Awards Exposure
Building blocks for execution For personal use only Media & Awards Exposure Unique nature of Osteopore’s products and procedures provides the Company with a high level of public exposure Business Model through media coverage and prestigious Innovation Award 2018 awards Recent coverage of Australian
Slide 28: Management Team
Building blocks for execution For personal use only 28 Management Team Geoff Pocock Goh Khoon Seng Executive Director Chief Executive Officer Formerly Managing Director of Hazer Mr Goh has a 30-year career spaning both start-ups and Group Ltd (ASX:HZR) and Non-Executive global multinational corporat
Slide 29: ASX Peers Show Potential for Value Re-rating
Building blocks for execution 29 For personal use only ASX Peers Show Potential for Value Re-rating PolyNovo (ASX: PNV) Medical devices for the treatment of burns, AU$13.6m Revenue FY19 $1.65bn Market Cap surgical wounds and Negative Pressure Wound Therapy. Mesoblast (ASX: MSB) Cellular medicines to
Slide 30: For personal use only
Investor Presentation 2019 For personal use only Geoff Pocock Executive Director M +61 412 194 373 E: geoff_pocock@osteopore.com